Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats

Journal of Ethnopharmacology

Volumn 124, Issue 1, 2009, Pages 142-150

  Cheung, K F ^a   Ye, D W ^a   Yang, Z F ^a   Lu, L ^a   Liu, C H ^b   Wang, X L ^b   Poon, R T P ^a   Tong, Y ^c   Liu, P ^b   Chen, Y C ^a   Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fuzheng Huayu Recipe; Hepatic fibrosis; Hepatic stellate cell; PDGF; Radix Salviae Miltiorrhizae; TGF 1; TIMP 1; Traditional Chinese Medicine

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; FUZHENG HUAYU; HERBACEOUS AGENT; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION REGULATION; GYNOSTEMMA PENTAPHYLLUM; HISTOPATHOLOGY; LIVER FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; SALVIA MILTIORRHIZA; SCHISANDRACEAE;

ACTINS; ALANINE TRANSAMINASE; ANGIOSPERMS; ANIMALS; CARBON TETRACHLORIDE; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS; MALE; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

RATTUS;

EID: 67349155604     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2009.03.005     Document Type: Article

References (38)

1. Afdhal N.H. The natural history of hepatitis C. Seminars in Liver Disease 24 (2004) 3-8
2. Bataller R., and Brenner D.A. Liver fibrosis. Journal of Clinical Investigation 115 (2005) 209-218
3. Bissell D.M., Roulot D., and George J. Transforming growth factor beta and the liver. Hepatology 34 (2001) 859-867
4. Borkham-Kamphorst E., Herrmann J., Stoll D., Treptau J., Gressner A.M., and Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Laboratory Investigation 84 (2004) 766-777
5. Borkham-Kamphorst E., Stoll D., Gressner A.M., and Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochemical and Biophysical Research Communications 321 (2004) 413-423
6. Chan K., and Lee H. The Way Forward For Chinese Medicine (2002), Taylor & Francis, London, New York
7. Chor S.Y., Hui A.Y., To K.F., Chan K.K., Go Y.Y., Chan H.L.Y., Leung W.K., and Sung J.J.Y. Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. Journal of Ethnopharmacology 100 (2005) 180-186
8. Claessonwelsh L. Platelet-derived growth-factor receptor signals. Journal of Biological Chemistry 269 (1994) 32023-32026
9. Dudas J., Kovalszky I., Gallai M., Nagy J.O., Schaff Z., Knittel T., Mehde M., Neubauer K., Szalay F., and Ramadori G. Expression of decorin, transforming growth factor-beta1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. American Journal of Clinical Pathology 115 (2001) 725-735
10. Friedman S.L. Liver fibrosis-from bench to bedside. Journal of Hepatology 38 (2003) S38-S53
11. Friedman S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nature Clinical Practice Gastroenterology & Hepatology 1 (2004) 98-105
12. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008) 1655-1669
13. Gines P., Cardenas A., Arroyo V., and Rodes J. Current concepts-management of cirrhosis and ascites. New England Journal of Medicine 350 (2004) 1646-1654
14. Hemmann S., Graf J., Roderfeld M., and Roeb E. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies. Journal of Hepatology 46 (2007) 955-975
15. Herbst H., Wege T., Milani S., Pellegrini G., Orzechowski H.D., Bechstein W.O., Neuhaus P., Gressner A.M., and Schuppan D. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. American Journal of Pathology 150 (1997) 1647-1659
16. Ikeda K., Wakahara T., Wang Y.Q., Kadoya H., Kawada N., and Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 29 (1999) 1760-1767
17. Inagaki Y., and Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56 (2007) 284-292
18. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11 (2004) 97-107
19. Lee T.Y., Wang G.J., Chiu J.H., and Lin H.C. Long-term administration of Salvia miltiorrhiza ameliorates carbon tetrachloride-induced hepatic fibrosis in rats. Journal of Pharmacy and Pharmacology 55 (2003) 1561-1568
20. Lin Y.L., Wu C.H., Luo M.H., Huang Y.J., Wang C.N., Shiao M.S., and Huang Y.T. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. Journal of Ethnopharmacology 105 (2006) 215-222
21. Liu C., Liu P., Liu C.H., Zhu X.Q., and Ji G. Effects of Fuzhenghuayu decoction on collagen synthesis of cultured hepatic stellate cells, hepatocytes and fibroblasts in rats. World Journal of Gastroenterology 4 (1998) 548-549
22. Liu P., Liu C., Xu L.M., Hu Y.Y., Xue H.M., Liu C.H., and Zhang Z.Q. Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B. World Journal of Gastroenterology 4 (1998) 348-353
23. Liu Y. The Essential Book of Traditional Chinese Medicine (1988), Columbia University Press, New York
24. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25 (2001) 402-408
25. Luk J.M., Wang X.L., Liu P., Wong K.F., Chan K.L., Tong Y., Hui C.K., Lau G., and Fan S.T. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver International 27 (2007) 879-890
26. McMahon B.J. Epidemiology and natural history of hepatitis B. Seminars in Liver Disease 25 (2005) 3-8
27. Mohammed F.F., Pennington C.J., Kassiri Z., Rubin J.S., Soloway P.D., Ruther U., Edwards D.R., and Khokha R. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 41 (2005) 857-867
28. Parsons C.J., Bradford B.U., Pan C.Q., Cheung E., Schauer M., Knorr A., Krebs B., Kraft S., Zahn S., Brocks B., Feirt N., Mei B.S., Cho M.S., Ramamoorthi R., Roldan G., Ng P., Lum P., Hirth-Dietrich C., Tomkinson A., and Brenner D.A. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40 (2004) 1106-1115
29. Pinzani M., Gesualdo L., Sabbah G.M., and Abboud H.E. Effects of platelet-derived growth-factor and other polypeptide mitogens on DNA-synthesis and growth of cultured rat-liver fat-storing cells. Journal of Clinical Investigation 84 (1989) 1786-1793
30. Proctor E., and Chatamra K. Controlled induction of cirrhosis in the rat. British Journal of Experimental Pathology 64 (1983) 320-330
31. Roderfeld M., Geier A., Dietrich C.G., Siewert E., Jansen B., Gartung C., and Roeb E. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver International 26 (2006) 579-586
32. Sangiovanni A., Prati G.M., Fasani P., Ronchi G., Romeo R., Manini M., Del Ninno E., Morabito A., and Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43 (2006) 1303-1310
33. Schuppan D., Ruehl M., Somasundaram R., and Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Seminars in Liver Disease 21 (2001) 351-372
34. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcoholism-Clinical and Experimental Research 23 (1999) 911-916
35. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G., Omata M., and Grp I.S. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Annals of Internal Medicine 131 (1999) 174-181
36. Yoshiji H., Kuriyama S., Miyamoto Y., Thorgeirsson U.P., Gomez D.E., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Tsujinoue H., Nakatani T., Thorgeirsson S.S., and Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32 (2000) 1248-1254
37. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Yanase K., Namisaki T., Imazu H., and Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36 (2002) 850-860
38. Zhou X.Y., Hovell C.J., Pawley S., Hutchings M.I., Arthur M.J.P., Iredale J.P., and Benyon R.C. Expression of matrix metalloproteinase-2 and-14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver International 24 (2004) 492-501